Cullinan Therapeutics (CGEM) Income from Continuing Operations (2020 - 2026)

Cullinan Therapeutics' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 52352000.0 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 7.47% year-over-year to 52352000.0 in Q1 2026; TTM through Mar 2026 was 224795000.0, a 28.16% increase from a year earlier, with the FY2025 full-year figure at 219879000.0, down 66.39% from the prior year.
• Income from Continuing Operations eased to 52352000.0 in Q1 2026 per CGEM's latest filing, from 50653000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 174065000.0 in Q2 2022 and bottomed at 178475000.0 in Q4 2024.
• The 5-year median for Income from Continuing Operations is 45002000.0 (2024), against an average of 38390529.41.
• Biggest YoY gain for Income from Continuing Operations was 1158.85% in 2022; the steepest drop was 1008.53% in 2022.
• Year by year, Income from Continuing Operations stood at 27046000.0 in 2022, then tumbled by 98.86% to 53785000.0 in 2023, then slumped by 231.83% to 178475000.0 in 2024, then soared by 71.62% to 50653000.0 in 2025, then dropped by 3.35% to 52352000.0 in 2026.
• Per Business Quant, the three latest CGEM Income from Continuing Operations figures stand at 52352000.0 (Q1 2026), 50653000.0 (Q4 2025), and 51740000.0 (Q3 2025).